Ginkgo provides update on its restructuring process including an acceleration of site consolidation initiatives and continued progress on cost reductions Ginkgo signs ...

Analysts expect the Cambridge, Massachusetts-based company to report a quarterly loss at $1.9 per share, versus a year-ago loss of $9.53 per share. Moderna projects to report revenue of $1.25 billion ...

Foghorn Therapeutics, Inc. ( (FHTX) ) has released its Q3 earnings. Here is a breakdown of the information Foghorn Therapeutics, Inc. presented ...

CAMBRIDGE, MA / ACCESSWIRE / October 31, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced its participation in the following upcoming investor conferences: Guggenheim's Inaugural Healthcare ...

In this article, we are going to take a look at where Merck & Co., Inc. (NYSE ... MRNA), a biotechnology company based in Cambridge, Massachusetts, were among the most sought-after due to their ...

Spyros Papapetropoulos, M.D., Ph.D., President and CEO of Bionomics, will deliver a company presentation during the Neuroscience Spotlight session taking place on Tuesday, November 12 at 1:00 p.m. ET ...

Former Merck & Co. executive Bruce Beutel ... On Tuesday, they launched the Cambridge, Massachusetts–based firm publicly and announced it had raised $20 million in seed funding led by Breakout ...

For the most current information about the device indications for the therapeutic products in this group, go to: ...

GSK said it is paying $2.1 billion upfront for Cambridge, Massachusetts-based Affinivax ... That rise came despite the approval of Merck & Co's 15-valent Vaxneuvance in July 2021, which has ...